Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

52.17 +1.86 (+3.70%)
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO 
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Oral presentations include new Decipher treatment-selection evidence and an OPTIMA breast cancer health economic analysis 
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer 
From Veracyte, Inc.
Via GlobeNewswire
Veracyte (NASDAQ:VCYT): Affordable Growth Backed by Strong Fundamentals ↗
Via Chartmill
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flow ↗
Via Chartmill
Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential ↗
Via Chartmill
News headline image
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026 
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment... 
From Veracyte, Inc.
Via GlobeNewswire
Veracyte (NASDAQ:VCYT) Smashes Q2 Estimates but Full-Year Guidance Disappoints, Shares Fall ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near Resistance ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT): A High Growth Stock With a Strong Technical Breakout Setup ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Fits the Affordable Growth Profile ↗
Via Chartmill
High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT) ↗
Via Chartmill
News headline image
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey 
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte Q2 Earnings Call Highlights ↗
Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD... 
Via MarketBeat
Topics Earnings
News headline image
Veracyte Announces Second Quarter 2026 Financial Results
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction. ↗
This genomic diagnostics company saw a notable insider sale, as shares have surged over 70% in the past year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally ↗
This genomics diagnostics specialist, up over 120% in a year, reported a notable insider sale amid ongoing scheduled dispositions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
From Veracyte
Via Business Wire
News headline image
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
From Veracyte, Inc.
Via Business Wire
News headline image
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
From Veracyte
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.